

Clinuvel opens R&D centre in Singapore

31 August 2020 | News

Bespoke Research & Development Centre to advance innovative pharmaceutical and OTC products



Australia based CLINUVEL Group has announced the opening of its state-of-the-art centralized Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd.

The extensive bespoke analytical and biological laboratories and offices will house and advance CLINUVEL's innovative R&D projects, expanding capacities in molecular profiling, peptide chemistry, and polymer and formulation sciences, as well as the capability to conduct ex vivo experiments and bioassays, and studies on fresh biological and tissue cultures.

CLINUVEL is focused on innovative areas of medicine with VALLAURIX developing drugs from the family of melanocortins and complementary over-the-counter (OTC) consumer products. In July the Company announced the first novel products from the VALLAURIX laboratories, liquid injectable formulations known as PRÉNUMBRA®.

In recent years CLINUVEL has controlled its investments in new product development, building dedicated scientific teams worldwide and now opening its purpose-built facility in Singapore to expedite our research," CLINUVEL's Chief Scientific Officer, Dr Dennis Wright said.

"Our research work with melanocortins – which target cells across the body and are known to have protective, anti-inflammatory and vasoactive effects, amongst others – focuses on translating our new molecules into safe, effective and clinically accepted pharmaceutical drugs for unmet patient needs. With CLINUVEL's first product already approved and being used to treat patients in Europe and the USA, the VALLAURIX teams are working on second-generation melanocortins, as well as OTC products which leverage our expertise in related fields. The new facilities will enable VALLAURIX to conduct a greater diversity of work inhouse, faster and more efficiently," Dr Wright said.

In April 2020, the Singapore Economic Development Board (EDB) reviewed VALLAURIX's scientific results and progress and decided to award up to S\$500,000 under their Research Incentive Scheme for Companies (RISC). This award is offered by

the Singaporean government to incentivize CLINUVEL to base its research on high values technologies in Singapore. Final inspection and certification will see the facility operating under ISO 17025 and conforming to Good Laboratory Practice.